Advertisement

Blockierung der S2-Rezeptoren — Ein neues Behandlungsprinzip bei der generalisierten Tendomyopathie (GTM)?

  • T. Stratz
  • P. Mennet
  • W. Müller
Conference paper

Summary

In a pilot study, the effectiveness of the S2-receptor blocker ketanserin was investigated in patients receiving concurrent physiotherapy for primary fibromyalgia. This combined treatment was compared with physiotherapy alone.

In the group treated with ketanserin, a significant reduction in spontaneous pain was observed, and the painfulness of “tender points” also decreased markedly. The patients experienced a significant improvement in the quality of sleep, the feeling of being rested after sleep, and psychiological well-being in the evening. Significant improvement was also recorded on the von Zerssen Mood Scale and the Erlanger Anxiety Scale. In the group receiving physiotherapy alone, the improvements were far less marked and usually were below the significance level.

These results are now being verified in a double-blind, randomized trial.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Dinerman H, Goldenberg DL, Felson DT (1986) A prospective evaluation of 118 patients with the fibromyalgia syndrome: prevalence of Raynaud’s phenomenon, Sicca symptoms. ANA, low complement, and Ig deposition at the dermal-epidermal junction. J Rheumatol 13: 368–373Google Scholar
  2. 2.
    Galster JV, Spörl G (1979) Entwicklung einer Skala zur Quantifizierung transitorischer und habitueller Angstzustände. Neurol Psychiat 5: 223–226Google Scholar
  3. 3.
    Görtelmeyer R (1985) On the Development of an Standardized Sleep Inventory for the Assessment of Sleep Methods of Sleep Research. G. Fischer, StuttgartGoogle Scholar
  4. 4.
    Grobecker H (1985) Serotonin und kardiovaskuläre Erkrankungen. MMW 127: 151–152Google Scholar
  5. 5.
    Idzikowski C (1989) The Effects of Ritanserin and Seganserin on Human Slow Wave Sleep. In: Wagnier A, Dugovic C, Radulovacki M (eds) Slow wave sleep. Raven Press, New YorkGoogle Scholar
  6. 6.
    Iverfeldt K, Peterson LL, Brondin E, Ögren S, Bartfai T (1986) Serotonin type-2 receptor mediated regulation of substance P release in the ventral spinal cord and the effects of chronic antidepressant treatment. Naunyn-Schmiedebergs Arch Pharmacol 333: 1–6PubMedCrossRefGoogle Scholar
  7. 7.
    Lautenschläger J, Brückte W, Schnorrenberger CC, Müller W (1988) Die Messung von Druckschmerzen im Bereich von Sehnen und Muskeln bei Gesunden und Patienten mit generalisierter Tendomyopathie ( Fibromyalgie-Syndrom ). Z Rheumatol 47: 397–404Google Scholar
  8. 8.
    Moldofsky H, Scarisbrick P, England R, Smythe HA (1975) Musculosceletal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” as healthy subjects. Psychosom Med 37: 341PubMedGoogle Scholar
  9. 9.
    Müller W, Lautenschläger J (1990) Die generalisierte Tendomyopathie (GTM). Teil I: Klinik, Verlauf und Differentialdiagnose. Z Rheumatol 49:11–21. - Teil II: Pathogenese und Therapie. Z Rheumatol 49: 22–29Google Scholar
  10. 10.
    Petraclia F, Facchinetti F, Matignoni E, Nappi E, Volpe G, Genazzani A (1984) Serotoninergic Agonists increase plasma levels of Betaendorphin and Betalipoprotein in humans. J Clin Endocrinol Metab 59: 1138–1142CrossRefGoogle Scholar
  11. 11.
    Takahashi Y, Kipnis DM, Daughaday WH (1968) Growth hormone secretion during sleep. J Clin Invest 47: 20CrossRefGoogle Scholar
  12. 12.
    Wolfe F, Hawley DJ, Cathey MA, Carox J, Rüssel J (1985) Fibrositis: Symptom frequency and criteria for diagnosis. J Rheumatol 12: 1159PubMedGoogle Scholar
  13. 13.
    Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL (1981) Primary fibromyalgia (Fibrositis). Clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 11: 151PubMedCrossRefGoogle Scholar
  14. 14.
    Vaeroy H, Helle R, Forre O, Kass E, Terenius L (1988) Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32: 21–26PubMedCrossRefGoogle Scholar
  15. 15.
    Zerssen D von, Koller DM, Rey ER (1970) Befindlichkeitsskala (BS), ein einfaches Instrument zur Objektivierung von Befindlichkeitsstörungen insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneimittelforschung (Drug Res) 20Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1991

Authors and Affiliations

  • T. Stratz
    • 1
  • P. Mennet
    • 1
  • W. Müller
    • 1
  1. 1.Hochrhein-Institut für Rheumaforschung und RheumapräventionBad SäckingenDeutschland

Personalised recommendations